2024 AAD Annual Meeting Recap: Day 3

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Adam Friedman, MD, FAAD: Exploring the Utilization of Immunomodulators as Therapeutic Interventions in Chronic Spontaneous Urticaria

In addition to recapping key highlights from his session, Friedman discusses what is new or upcoming in dermatology that most excites him.

Anticipated FDA Approval of Bimekizumab for HS: Insights From Investigator Christopher Sayed, MD

The phase 3 studies, BE HEARD I and BE HEARD II, showed significant improvements in skin pain over the 48-week period.

Trends in Cosmeceuticals and Nutraceuticals: Exosomes and Adaptogens Take Center Stage

Discover the science behind cosmeceutical advancements and the importance of staying informed for enhanced patient care with Zoe Diana Draelos, MD.

Alan Mendelsohn, MD, Shares Insights Into Congenital Ichthyosis Patient Care and the Development of TMB-001

The congenital ichthyosis session the 2024 AAD Annual Meeting covered real-world patient cases and treatments on the horizon.

Surgical Procedures to Consider for Hidradenitis Suppurativa

Maria Aleshin, MD, FAAD, presented surgical procedures for HS that can be performed in the office.

How is Artificial Intelligence Growing Up?

Joseph Zabinski, PhD, MEM, of OM1, shares insights at AAD into how artificial intelligence can mature and be a positive tool for disease detection.

Lawrence Eichenfield, MD: Outlining Late-Breaking INTEGUMENT-PED Data for Roflumilast in Pediatric Patients

Eichenfield discusses the late-breaking data on roflumilast cream 0.05% in the pediatric patient population and its implications.

Johnson & Johnson Reveals Promising Results for JNJ-2113 in FRONTIER 2 Study

Lloyd Miller, MD, PhD, delves into the new data demonstrating high rates of skin clearance over 52 weeks in adults with moderate to severe plaque psoriasis.

Discussing Late-Breaking INTEGUMENT-PED Data With Arcutis' Chief Medical Officer, Patrick Burnett, MD, PhD, FAAD

Burnett recently spoke with Dermatology Times to discuss the background, methods, and findings of the late-breaking INTEGUMENT-PED data, as well as its potential real-world and clinical implications.

Late-Breaking Data: Long-Term Safety and Efficacy of Delgocitinib Cream for Chronic Hand Eczema

Melinda Gooderham, MSc, MD, FRCPC, provided insights into the significance of the DELTA 3 extension data presented at AAD 2024.

Navigating Finances in Dermatology: Top 5 Considerations for Dermatologists

In an exclusive interview with Gary Dudzik, he shared top 5 considerations dermatology clinicians should have when choosing financial services for their practices and overall financial goals.

Late-Breaking Data: Long-Term Safety and Efficacy of Largest Prurigo Nodularis Study Ever Conducted

Shawn Kwatra, MD, presented late-breaking data at AAD 2024 on the largest prurigo nodularis and nemolizumab clinical trial, OLYMPIA.